User profiles for AI Tukhvatulin

Amir Tukhvatulin

NFGamaleya National Research Center for Epidemiology and Microbiology
Verified email at gamaleya.org
Cited by 4788

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in …

…, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin… - The Lancet, 2021 - thelancet.com
Background A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac
(Sputnik V), showed a good safety profile and induced strong humoral and cellular immune …

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1 …

…, IV Dolzhikova, OV Zubkova, AI Tukhvatulin… - The Lancet, 2020 - thelancet.com
Background We developed a heterologous COVID-19 vaccine consisting of two components,
a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (…

Toll-like receptors (TLRs): the role in tumor progression

…, DY Logunov, AI Tukhvatulin… - Acta Naturae …, 2010 - cyberleninka.ru
Toll-like receptors (TLRs) are major components of the innate immune system that recognize
the conserved molecular structures of pathogens (pathogen-associated molecular patterns; …

Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3) and Moscow endemic …

…, AG Botikov, AV Kuzina, DM Grousova, AI Tukhvatulin… - Vaccines, 2021 - mdpi.com
Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have
been used in mass vaccination companies around the world. Virus neutralization and …

[HTML][HTML] An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus …

AI Tukhvatulin, IV Dolzhikova… - The Lancet Regional …, 2021 - thelancet.com
Background While the world is experiencing another wave of COVID-19 pandemic, global
vaccination program is hampered by an evident shortage in the supply of licensed vaccines. …

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

IV Dolzhikova, OV Zubkova, AI Tukhvatulin… - Human vaccines & …, 2017 - Taylor & Francis
Ebola hemorrhagic fever, also known as Ebola virus disease or EVD, is one of the most
dangerous viral diseases in humans and animals. In this open-label, dose-escalation clinical trial…

Virus-vectored Ebola vaccines

…, AS Dzharullaeva, AI Tukhvatulin… - Acta Naturae …, 2017 - cyberleninka.ru
The Ebola virus disease (EVD) is one of the most dangerous infections affecting humans
and animals. The first EVD outbreaks occurred in 1976 in Sudan and Zaire. Since then, more …

Receptor Mincle promotes skin allergies and is capable of recognizing cholesterol sulfate

…, B Lepenies, AI Tukhvatulin… - Proceedings of the …, 2017 - National Acad Sciences
Sterile (noninfected) inflammation underlies the pathogenesis of many widespread diseases,
such as allergies and autoimmune diseases. The evolutionarily conserved innate immune …

Camelid VHHs fused to human fc fragments provide long term protection against botulinum neurotoxin a in mice

…, AI Solovyev, IB Esmagambetov, AI Tukhvatulin… - Toxins, 2019 - mdpi.com
The bacterium Clostridium botulinum is the causative agent of botulism—a severe intoxication
caused by botulinum neurotoxin (BoNT) and characterized by damage to the nervous …

Retention of neutralizing response against SARS-CoV-2 omicron variant in sputnik V-Vaccinated individuals

…, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin… - Vaccines, 2022 - mdpi.com
The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly spreading
all around the world. Omicron has become the dominant variant of SARS-CoV-2. There …